0001192482-13-000213.txt : 20131211
0001192482-13-000213.hdr.sgml : 20131211
20131211180716
ACCESSION NUMBER: 0001192482-13-000213
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131211
FILED AS OF DATE: 20131211
DATE AS OF CHANGE: 20131211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001361248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-889-9900
MAIL ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schmitt Paul J
CENTRAL INDEX KEY: 0001390406
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36208
FILM NUMBER: 131271961
MAIL ADDRESS:
STREET 1: PA EARLY STAGE PARTNERS
STREET 2: 1200 LIBERTY RIDGE DRIVE, SUITE 310
CITY: WAYNE
STATE: PA
ZIP: 19087
3
1
edgar.xml
PRIMARY DOCUMENT
X0206
3
2013-12-11
0
0001361248
TETRALOGIC PHARMACEUTICALS CORP
TLOG
0001390406
Schmitt Paul J
C/O NOVITAS CAPITAL III, L.P.
116 RESEARCH DRIVE
BETHLEHEM
PA
18015
1
0
0
0
Series A Convertible Preferred Stock
Common Stock
261437
I
See footnote
Series B Convertible Preferred Stock
Common Stock
179738
I
See footnote
Series C Convertible Preferred Stock
Common Stock
427440
I
See footnote
Series B Preferred Stock Warrants
7.65
2016-03-30
Common Stock
2723
I
See footnote
Series B Preferred Stock Warrants
7.65
2016-05-05
Common Stock
2723
I
See footnote
Common Stock Warrants
.85
Common Stock
8742
I
See footnote
Common Stock Warrants
.85
Common Stock
10491
I
See footnote
Convertible Notes
Common Stock
I
See footnote
Series C Warrants
6.4022
Common Stock
I
See footnote
The Series A Convertible Preferred Stock will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and has no expiration date.
The Series B Convertible Preferred Stock will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and has no expiration date.
The Series C Convertible Preferred Stock will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and has no expiration date.
The warrants are immediately exercisable.
The warrants are immediately exercisable. The warrants expire on the later of 11/25/2019 or five years after the consummation of the Company's initial public offering.
The warrants are immediately exercisable. The warrants expire on the later of 03/10/2020 or five years after the consummation of the Company's initial public offering.
The Convertible Notes and Accrued Interest will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and have no expiration date.
Warrants will be automatically exercised immediately prior to the closing of the Issuer's initial public offering. Warrants are exercisable for a number of shares of common stock equal to the warrant amount divided by the exercise price and will be net exercised at the initial public offering price.
The securities are held of record by by Novitas Capital III, LP. ("Novitas III"), Novitas Capital III GP, LP ("Novitas GP") and Novitas Capital III GP Manager, LLC ("Novitas Manager"). Novitas GP is the general partner of Novitas III and Novitas Manager is the general partner of Novitas GP. Mr. Schmitt disclaims beneficial ownership of the shares beneficially owned by Novitas III, Novitas GP and Novitas Manager, except to the extent of his pecuniary interest therein.
/s/ Richard L. Sherman, Attorney-In-Fact for Paul Schmitt
2013-12-11